CHARLOTTESVILLE, Virginia, June 23, 2015 /PRNewswire/ — Biovista Inc. today announced the publication of data from research it carried out in collaboration with the FDA and Israeli HMO Clalit, focusing on the prediction of risk factors related to targeted diseases. The research, published in the American Diabetes Association journal Diabetes Care, identifies hypothyroidism as a … Read More
News
Can drug development learn from Apple’s Music strategy?
Apple’s strategy for its Apple Music service may offer an apt analogy to help us reframe the therapy research and development enterprise.
“Attacking Beehive” therapeutic strategies: the promise of drug combinations
Drug combinations make sense both from the science and from the business perspective.
Big Data Analytics – the new microscope
Like systematic drug repurposing, big data analytics recognises that there is value in “knowing what we know”. Both can lead to innovation and both can play a significant role in shaping the healthcare environment of the future.
Predicting risk factors and drug side effects: opportunities and challenges
Recent Biovista work that shows it is possible to predict risk factors reliably, clears the way to systematic use of this capability by the healthcare industry.